S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Earnings Date, Estimates & Call Transcripts

$783.13
+31.93 (+4.25%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$758.63
$789.95
50-Day Range
$680.49
$783.13
52-Week Range
$538.01
$789.95
Volume
1.45 million shs
Average Volume
631,572 shs
Market Capitalization
$85.28 billion
P/E Ratio
20.48
Dividend Yield
N/A
Price Target
$798.65

Earnings Summary

Upcoming
Earnings Date
May. 3Estimated
Actual EPS
(Feb. 3)
$12.56 Beat By $4.38
Consensus EPS
(Feb. 3)
$8.18
Last Year's Q1 EPS
(2/4/2022)
$23.72
Skip Charts & View Estimated and Actual Earnings Data

REGN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

REGN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Regeneron Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20233$9.07$11.49$10.43
Q2 20233$9.65$11.17$10.41
Q3 20233$9.63$11.41$10.81
Q4 20233$9.54$11.17$10.46
FY 202312$37.89$45.24$42.11

REGN Earnings Date and Information

Regeneron Pharmaceuticals last issued its quarterly earnings data on February 3rd, 2023. The biopharmaceutical company reported $12.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.18 by $4.38. The company earned $3.41 billion during the quarter, compared to analysts' expectations of $3.11 billion. Its revenue was down 31.1% compared to the same quarter last year. Regeneron Pharmaceuticals has generated $38.24 earnings per share over the last year ($38.24 diluted earnings per share) and currently has a price-to-earnings ratio of 20.5. Earnings for Regeneron Pharmaceuticals are expected to grow by 10.58% in the coming year, from $36.78 to $40.67 per share. Regeneron Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 3rd, 2023 based off prior year's report dates.

Regeneron Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/3/2023
(Estimated)
        
2/3/2023Q4 22$8.18$12.56+$4.38$11.42$3.11 billion$3.41 billion    
11/3/2022Q3 2022$8.55$9.98+$1.43$8.30$2.79 billion$2.94 billion
8/3/2022Q2 2022$8.53$9.77+$1.24$12.07$2.80 billion$2.86 billion    
5/4/2022Q1 2022$9.37$11.49+$2.12$14.37$2.69 billion$2.97 billion    
2/4/2022Q4 2021$18.49$23.72+$5.23$27.75$4.49 billion$4.95 billion    
11/4/20219/30/2021$9.81$15.37+$5.56$16.41$2.80 billion$3.45 billion    
8/5/20216/30/2021$8.81$25.80+$16.99$27.97$3.90 billion$5.14 billion    
5/6/20213/31/2021$7.78$9.89+$2.11$10.09$2.69 billion$2.53 billion  
2/4/202112/31/2020$7.11$9.53+$2.42$7.20$2.40 billion$2.42 billion  
11/5/20209/30/2020$9.52$8.36($1.16)$7.97$2.09 billion$2.29 billion  
8/5/20206/30/2020$5.59$7.16+$1.57$4.97$1.74 billion$1.95 billion  
5/5/20203/31/2020$6.13$6.60+$0.47$6.31$1.81 billion$1.83 billion  
2/6/2020Q4 2019$6.03$7.50+$1.47$6.23$2.10 billion$2.17 billion  
11/5/2019Q3 2019$5.13$6.67+$1.54$5.82$1.98 billion$2.05 billion  
8/6/2019Q2 2019$4.60$5.29+$0.69$8.90$1.80 billion$1.93 billion  
5/7/20193/31/2019$5.24$4.45($0.79)$3.51$1.76 billion$1.71 billion  
2/6/201912/31/2018$5.10$6.84+$1.74$4.69$1.73 billion$1.93 billion
11/6/20189/30/2018$4.94$5.87+$0.93$5.03$1.64 billion$1.66 billion
8/2/2018Q2 2018$4.60$5.45+$0.85$4.58$1.56 billion$1.61 billion
5/3/2018Q1 2018$5.08$4.67($0.41)$3.80$1.50 billion$1.51 billion
2/8/2018Q4 2017$4.18$5.23+$1.05$7.42$1.50 billion$1.58 billion
11/8/2017Q3 2017$3.83$3.99+$0.16$3.32$1.45 billion$1.50 billion
8/3/2017Q2 2017$2.67$4.17+$1.50$4.42$1.36 billion$1.47 billion  
5/4/2017Q1 2017$2.50$2.92+$0.42$2.16$1.30 billion$1.32 billion  
2/9/2017Q4 2016$2.51$2.19($0.32)$2.19$1.30 billion$1.23 billion  
11/4/2016Q3 2016$2.27$2.41+$0.14$2.55$1.29 billion$1.22 billion
8/4/2016Q2 2016$1.73$2.11+$0.38$2.53$1.24 billion$1.21 billion
5/5/2016Q1 2016$1.24$1.45+$0.21$1.45$1.18 billion$1.20 billion
2/9/2016Q4 2015$2.70$1.46($1.24)$1.58$1.17 billion$1.10 billion  
11/4/2015Q3 2015$2.62$2.59($0.03)$3.36$1.05 billion$1.14 billion  
8/4/2015Q2 2015$1.81$2.36+$0.55$3.03$887.03 million$999.00 million  
5/7/2015Q1 2015$2.50$1.99($0.51)$3.32$820.30 million$870.00 million
2/10/2015Q4 2014$2.08$2.11+$0.03$3.26$775.42 million$802.00 million
11/4/2014Q3 2014$2.10$1.90($0.20)$3.10$733.04 million$726.00 million
8/5/2014Q2 2014$2.33$1.89($0.44)$2.96$647.99 million$666.00 million  
5/8/2014Q1 2014$0.98$1.57+$0.59$2.56$609.04 million$626.00 million
2/11/2014Q4 2013$1.01$2.06+$1.05$3.26$579.17 million$610.00 million
11/5/2013Q3 2013$0.99$2.02+$1.03$2.79$501.93 million$597.00 million
8/6/2013Q2 2013$0.86$1.36+$0.50$1.93$470.63 million$458.00 million
5/3/2013Q1 2013$1.06$1.32+$0.26$1.74$424.26 million$440.00 million  
2/14/2013Q4 2012$1.11$1.47+$0.36$392.64 million$415.00 million  
10/24/2012$1.14$1.89+$0.75  
7/25/2012$0.45$0.90+$0.45
4/26/2012($0.33)$0.37+$0.70
2/13/2012($0.60)($0.37)+$0.23  
10/27/2011Q3 2011($0.75)($0.68)+$0.07($0.68)
7/28/2011($0.40)($0.69)($0.29)
5/3/2011Q1 2011($0.38)($0.49)($0.11)($0.49)
2/17/2011Q4 2010($0.32)($0.17)+$0.15($0.17)
10/28/2010Q3 2010($0.34)($0.41)($0.07)($0.41)
7/28/2010Q2 2010($0.38)($0.31)+$0.07($0.31)
4/29/2010Q1 2010($0.49)($0.38)+$0.11($0.38)
2/18/2010Q4 2009($0.34)($0.46)($0.12)($0.46)
11/3/2009Q3 2009($0.23)($0.01)+$0.22($0.01)
8/4/2009Q2 2009($0.28)($0.19)+$0.09($0.19)
4/30/2009Q1 2009($0.29)($0.22)+$0.07($0.22)
2/26/2009Q4 2008($0.30)($0.40)($0.10)($0.40)
11/4/2008Q3 2008($0.32)($0.27)+$0.05($0.27)
7/31/2008Q2 2008($0.35)($0.22)+$0.13($0.20)
5/1/2008Q1 2008($0.34)($0.15)+$0.19($0.15)
2/27/2008Q4 2007($0.46)($0.19)+$0.27($0.19)












Regeneron Pharmaceuticals Earnings - Frequently Asked Questions

When is Regeneron Pharmaceuticals's earnings date?

Regeneron Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 3rd, 2023 based off last year's report dates. Learn more on REGN's earnings history.

Did Regeneron Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) reported $12.56 earnings per share (EPS) to beat the analysts' consensus estimate of $8.18 by $4.38. Learn more on analysts' earnings estimate vs. REGN's actual earnings.

How can I listen to Regeneron Pharmaceuticals's earnings conference call?

The conference call for Regeneron Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Regeneron Pharmaceuticals's conference call transcript?

The conference call transcript for Regeneron Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Regeneron Pharmaceuticals generate each year?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded annual revenue of $16.07 billion.

How much profit does Regeneron Pharmaceuticals generate each year?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded net income of $8.08 billion. REGN has generated $38.24 earnings per share over the last four quarters.

What is Regeneron Pharmaceuticals's price-to-earnings ratio?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a trailing price-to-earnings ratio of 20.48 and a forward price-to-earnings ratio of 21.29. The price/earnings-to-growth ratio is 2.37.

What is Regeneron Pharmaceuticals's EPS forecast for next year?

Regeneron Pharmaceuticals's earnings are expected to grow from $36.78 per share to $40.67 per share in the next year, which is a 10.58% increase.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:REGN) was last updated on 2/5/2023 by MarketBeat.com Staff